Research Papers:

Secreted miR-210-3p as non-invasive biomarker in clear cell renal cell carcinoma

Vincenzo Petrozza, Antonio Luigi Pastore, Giovanni Palleschi, Claudia Tito, Natale Porta, Serena Ricci, Chiara Marigliano, Manuela Costantini, Giuseppe Simone, Angelina Di Carlo, Michele Gallucci, Antonio Carbone and Francesco Fazi _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:69551-69558. https://doi.org/10.18632/oncotarget.18449

Metrics: PDF 2315 views  |   HTML 2401 views  |   ?  


Vincenzo Petrozza1,*, Antonio Luigi Pastore2,*, Giovanni Palleschi2, Claudia Tito3, Natale Porta1, Serena Ricci4, Chiara Marigliano5, Manuela Costantini6,7, Giuseppe Simone7, Angelina Di Carlo4, Michele Gallucci7, Antonio Carbone2,* and Francesco Fazi3,*

1Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Pathology Unit ICOT, Latina, Italy

2Department of Medico Surgical Sciences and Biotechnologies, Sapienza University of Rome, Urology Unit ICOT, Latina, Italy

3Department of Anatomical, Histological, Forensic & Orthopaedic Sciences, Section of Histology & Medical Embryology, Sapienza University of Rome, Rome, Italy

4Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy

5Department of Radiological Sciences, Oncology and Pathology, Azienda Policlinico Umberto I, Sapienza University of Rome, Rome, Italy

6Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, Italy

7Department of Urology, Regina Elena National Cancer Institute of Rome, Rome, Italy

*These authors have contributed equally to this work

Correspondence to:

Francesco Fazi, email: [email protected]

Antonio Carbone, email: [email protected]

Keywords: microRNAs, biomarkers, ccRCC, miR-210-3p, urine specimens

Received: January 16, 2017     Accepted: May 06, 2017     Published: June 13, 2017


The most common subtype of renal cell carcinoma (RCC) is clear cell RCC (ccRCC). It accounts for 70-80% of all renal malignancies representing the third most common urological cancer after prostate and bladder cancer. The identification of non-invasive biomarkers for the diagnosis and responsiveness to therapy of ccRCC may represent a relevant step-forward in ccRCC management. The aim of this study is to evaluate whether specific miRNAs deregulated in ccRCC tissues present altered levels also in urine specimens. To this end we first assessed that miR-21-5p, miR-210-3p and miR-221-3p resulted upregulated in ccRCC fresh frozen tissues compared to matched normal counterparts. Next, we evidenced that miR-210-3p resulted significantly up-regulated in 38 urine specimens collected from two independent cohorts of ccRCC patients at the time of surgery compared to healthy donors samples. Of note, miR-210-3p levels resulted significantly reduced in follow-up samples. These results point to miR-210-3p as a potential non-invasive biomarker useful not only for diagnosis but also for the assessment of complete resection or response to treatment in ccRCC management.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18449